PLASMA CELL MYELOMA REFRACTORY
Clinical trials for PLASMA CELL MYELOMA REFRACTORY explained in plain language.
Never miss a new study
Get alerted when new PLASMA CELL MYELOMA REFRACTORY trials appear
Sign up with your email to follow new studies for PLASMA CELL MYELOMA REFRACTORY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat myeloma: umbrella trial tests smarter drug cocktails
Disease control Recruiting nowThis study is for people with multiple myeloma that has come back or stopped responding to treatment. It tests different combinations of the drug isatuximab with newer agents, with or without dexamethasone, to see which works best. About 258 adults will take part, and the goal is…
Matched conditions: PLASMA CELL MYELOMA REFRACTORY
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New shot delivery system could ease multiple myeloma treatment
Disease control Recruiting nowThis study tests a new way to give the drug isatuximab for multiple myeloma that has returned or not responded to treatment. About 64 adults will receive isatuximab through a small device worn on the body, along with two other drugs. The goal is to see if this combination can shr…
Matched conditions: PLASMA CELL MYELOMA REFRACTORY
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New shot shows promise for Hard-to-Treat blood cancer
Disease control Recruiting nowThis early-stage study tests a new antibody drug (SAR446523) given as a shot under the skin for people with multiple myeloma that has come back or stopped responding to treatment. The study has two parts: first, finding the safest dose, and then comparing two dose schedules to se…
Matched conditions: PLASMA CELL MYELOMA REFRACTORY
Phase: PHASE1 • Sponsor: Sanofi • Aim: Disease control
Last updated May 06, 2026 16:15 UTC